Journal of Medical Economics
Volume 27, 2024 - Issue 1
Oncology
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo
Siguroli Teitssona Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]
https://orcid.org/0009-0001-7378-1675
https://orcid.org/0009-0001-7378-1675, Thor-Henrik Brodtkorbb RTI Health Solutions, Ljungskile, Swedenhttps://orcid.org/0000-0002-9899-233X
https://orcid.org/0000-0002-9899-233X, , Miraj Y. Patelc Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0002-3543-1420
https://orcid.org/0000-0002-3543-1420, , , & Stephen Palmere Centre for Health Economics, University of York, York, UKhttps://orcid.org/0000-0002-7268-2560
https://orcid.org/0000-0002-7268-2560 show all